Open Label Safety and Efficacy Study of Levetiracetam in Korean Patients With Epilepsy

Inclusion Criteria: * Subjects with epilepsy experiencing partial seizures, whether or not secondarily generalized. * Subjects must present between 3 and 42 partial seizures over the three months prior to protocol Visit 1. * Use of one (1), but no more than two (2) concomitant marketed AEDs at the time of trial entry. Exclusion Criteria: * Subjects on felbamate with less than 18 months exposure. * Subjects on vigabatrin, whose visual field has not been assessed as per recommendation of the manufacturer, i.e. every 6 months. * Presence of known pseudoseizures within the last year. * Presence of progressive cerebral disease, any other progressively degenerative neurological disease, or any cerebral tumors. * Uncountable seizures (clusters) or history of convulsive status epilepticus within the last five years.